Abstract:Background Colorectal cancer (CRC) frequently has a dysregulated epigenome causing aberrant up-regulation of oncogenes such as c-MYC. Bromodomain and extra-terminal domain (BET) proteins and histone acetyltransferases (HAT) are epigenetic regulatory proteins that create and maintain epigenetic states supporting oncogenesis. BET inhibitors and HAT inhibitors are currently being investigated as cancer therapeutics due to their ability to suppress cancer-promoting epigenetic modifiers. Due to the extensive molecular crosstalk between BET proteins and HAT proteins, we hypothesized that dual inhibition of BET and HAT could more potently inhibit CRC cells than inhibition of each individual protein. Methods We investigated the activity and mechanisms of a dual BET and HAT inhibitor, NEO2734, in CRC cell lines and mouse xenografts. MTS, flow cytometry, and microscopy were used to assess cell viability. qPCR, Western blotting, and immunofluorescent staining were used to assess mechanisms of action. Results We found that NEO2734 more potently suppresses CRC cell growth than first generation BET inhibitors, regardless of the status of common CRC driver mutations. We previously showed that BET inhibitors upregulate DR5 to induce extrinsic apoptosis. In the current study, we show that NEO2734 treatment induces CRC cell apoptosis via both the intrinsic and extrinsic apoptosis pathways. NEO2734 increases p53 expression and subsequently increased expression of the p53-upregulated mediator of apoptosis (PUMA), which is a critical mechanism for activating intrinsic apoptosis. We demonstrate that inhibition of either the intrinsic or extrinsic branches of apoptosis partially rescues CRC cells from NEO2734 treatment, while the dual inhibition of both branches of apoptosis more strongly rescues CRC cells from NEO2734 treatment. Finally, we show that NEO2734 monotherapy is able to suppress tumor growth in CRC xenografts by inducing apoptosis. Conclusions Our study demonstrates NEO2734 potently suppresses CRC cells in vitro and in vivo by simultaneously upregulating PUMA and DR5 to induce cell death. Further studies of NEO2734 for treating CRC are warranted.

Dual targeting of wild‐type p53 and gut microbiota by Magnolol represses key metabolic process and kills CRC cells

HMGA2 Promotes Resistance Against Paclitaxel by Targeting the P53 Signaling Pathway in Colorectal Cancer Cells

METTL14 Modulates Glycolysis to Inhibit Colorectal Tumorigenesis in P53-Wild-type Cells

Pharmacological Activation of the P53 Pathway Within the Tumor Microenvironment Induces Immunogenic Cell Death of Tumors and Enhances Antitumor Immunity

p53-responsive CMBL reprograms glucose metabolism and suppresses cancer development by destabilizing phosphofructokinase PFKP

P53 Induces Circfrmd4a to Suppress Cancer Development Through Glycolytic Reprogramming and Cuproptosis

Targeting Mtor Suppressed Colon Cancer Growth Through 4ebp1/eif4e/puma Pathway

MICAL2 Mediates P53 Ubiquitin Degradation Through Oxidating P53 Methionine 40 and 160 and Promotes Colorectal Cancer Malignance

Engineered microparticles modulate arginine metabolism to repolarize tumor-associated macrophages for refractory colorectal cancer treatment

p53 Orchestrates Cancer Metabolism: Unveiling Strategies to Reverse the Warburg Effect

Gut microbiome mediates ferroptosis resistance for colorectal cancer development

Unraveling the Role of TP53 in Colorectal Cancer Therapy: From Wild-Type Regulation to Mutant

p53 promotes peroxisomal fatty acid β-oxidation to repress purine biosynthesis and mediate tumor suppression

Restoration of the Tumor-Suppressor Function to Mutant P53 by Ganoderma Lucidum Polysaccharides in Colorectal Cancer Cells.

p53 promotes peroxisomal fatty acid beta-oxidation to repress purine biosynthesis and mediate tumor suppression

Metabolic Reprogramming of Colorectal Cancer Cells and the Microenvironment: Implication for Therapy

Mir-503-5p Confers Drug Resistance by Targeting PUMA in Colorectal Carcinoma

Dual inhibition of BET and HAT/p300 suppresses colorectal cancer via DR5- and p53/PUMA-mediated cell death

CAPG interference induces apoptosis and ferroptosis in colorectal cancer cells through the P53 pathway